AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00577824
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 5mcg, twice a day
Trial: NCT00577824
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 10mcg, twice a day
Trial: NCT01493973
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
Trial: NCT02954393
Drug: Metronidazole active phase
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
Trial: NCT02954393
Drug: Metronidazole healing phase
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
Trial: NCT02954393
Drug: Amoxicillin active phase
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
Trial: NCT00592176
Drug: local injection of bevacizumab
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
Trial: NCT02954393
Drug: Amoxicillin healing phase
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
Trial: NCT01329016
Drug: Glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
Trial: NCT01329016
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
Trial: NCT01329016
Drug: Glyburide-Metformin combination
RxNorm normalized name: glyburide / metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
Trial: NCT01956656
Drug: lotus leaf mouthwash
RxNorm normalized name: Lotus corniculatus flower volatile oil
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
Trial: NCT02728453
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
Trial: NCT03237390
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03237390
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02728453
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
Trial: NCT00764062
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin :drug
Trial: NCT00072332
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00072332
Drug: edotecarin
RxNorm normalized name: Edotecarin
DrugBank: Edotecarin (DB04882)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01890837
Drug: Daikenchuto (TU-100)
RxNorm normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
Trial: NCT01480310
Drug: MCAF5352A
RxNorm normalized name: MCAF5352A
DrugBank: Afasevikumab (DB14798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: may receive up to 3 subcutaneous doses of MCAF5352A
Trial: NCT00752687
Drug: ABT-072
RxNorm normalized name: ABT-072
DrugBank: ABT-072 (DB15156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
Trial: NCT00867113
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: imatinib mesylate was supplied in 100 and 400 mg tablets
Trial: NCT04379050
Drug: ABBV-951
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for continuous subcutaneous infusion (CSCI).
Trial: NCT03178708
Drug: Group A amantadine sulfate
RxNorm normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion solution for slowly intravenous application 3 hours preoperative
Trial: NCT00120640
Drug: 17 hydroxyprogesterone caproate intramuscular injections
RxNorm normalized name: Hydroxyprogesterone Caproate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01430806
Drug: Dronedarone arm
DrugBank: Dronedarone (DB04855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO Dronedarone 400 mg BID
Trial: NCT01430806
Drug: Dronedarone
RxNorm normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronedarone PO 400 MG BID
Trial: NCT01372670
Drug: Hydroxyzine
RxNorm normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID
Trial: NCT01372670
Drug: hydroxyzine HCL
RxNorm normalized name: hydroxyzine HCl
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxyzine HCL dosed on weight given 3x per day
Trial: NCT01473316
Drug: GDC-0980
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT01473316
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeating Oral Dose
Trial: NCT00004239
Drug: Compound 506U78
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01744353
Drug: Dose level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Trial: NCT01744353
Drug: Dose level 3
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Trial: NCT02257957
Drug: PRP injection
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02257957
Drug: Standard care Hyaluronic acid eye drops
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: : 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
Trial: NCT02482740
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: letrozole 2.5 mg qd was given for 12 months or till disease progress
Trial: NCT03257683
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study group will receive additional therapeutic dosing of drug.
Trial: NCT01431534
Drug: Ridaforolimus
RxNorm normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
Trial: NCT02482740
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tamoxifen was given 20 mg qd for 12 months or till disease progress
Trial: NCT00703430
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
Trial: NCT00048347
Drug: AVONEX
RxNorm normalized name: Avonex
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30µg IM every week for 12 weeks
Trial: NCT00902707
Drug: Mucinex 1200mg
RxNorm normalized name: guaifenesin 1200 MG [Mucinex]
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compared to Placebo
Trial: NCT03027557
Drug: Cinacalcet 30 mg Tablet
RxNorm normalized name: cinacalcet 30 MG
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in one arm will receive 30 mg cinacalcet each day.
Trial: NCT03027557
Drug: Denosumab Inj 60 mg/ml
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in two arms will receive 60 mg Denosumab biannually.
Trial: NCT02343406
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults: intravenous administration (1.25 mg/kg or 1.0 mg/kg body weight) over 30 to 40 minutes once every 2 weeks until one of the treatment withdrawal criteria was met. The dose was 1.25 mg/kg in the original protocol (Version 1) and Version 2, Amendment 1, and was lowered to 1.0 mg/kg in protocol Version 3, Amendment 2. Pediatric participants: Intravenous administration (1.0 mg/kg body weight for those who were 6 to 17 years old at the date of first dose, or 1.3 mg/kg for those who were 0 to 5 years old) over 30 to 40 minutes or as directed by the guidelines once every 2 weeks until one of the treatment withdrawal criteria was met, for a maximum of one year. If used in combination with temozolomide, depatuxizumab mafodotin was dosed on Day 1 and Day 15 of the TMZ cycle (assuming a standard regimen of 200 mg/m\^2/day for 5 days of each 28-day cycle; for other TMZ schedules, timing of the depatuxizumab mafodotin dosing schedule were to be discussed with the medical monitor).
Trial: NCT02343406
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules administered orally, 150 mg/m\^2 on Days 1-5 for the first 28-day cycle, with dose escalation to 200 mg/m\^2 in subsequent cycles in case of adequate tolerance until one of the treatment withdrawal criteria was met.
Trial: NCT02343406
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules administered orally, 110 mg/m\^2 on Day 1 of every 42-day treatment period. Treatment continued until one of the treatment withdrawal criteria was met, for a maximum of one year.
Trial: NCT00220584
Drug: donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
Trial: NCT00548145
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg by orally/day Duration: 12 months
Trial: NCT04716933
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion Q3W
Trial: NCT00874848
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Trial: NCT04716933
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion Q3W
Trial: NCT04716933
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion Q3W
Trial: NCT04716933
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral capsule once daily
Trial: NCT04716933
Drug: Placebo matching lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral capsule once daily
Trial: NCT00874848
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Trial: NCT04427098
Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
RxNorm normalized name: enoxaparin 40 mg/0.4 mL injectable solution
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin 40 mg once daily for 14 days.
Trial: NCT04427098
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight \>100 kg
Trial: NCT03528629
Drug: Zolbetuximab
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolbetuximab will be administered as a 2-hour intravenous infusion.
Trial: NCT01018511
Drug: Placebo tamsulosin hydrochloride OCAS 0.4 mg
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01018511
Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01018511
Drug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01018511
Drug: tamsulosin hydrochloride OCAS 0.4 mg
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01018511
Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01018511
Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03282123
Drug: Midomafetamine
RxNorm normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 to 120 mg MDMA
Trial: NCT04004000
Drug: Losmapimod
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination.
Trial: NCT00658411
Drug: deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
Trial: NCT02034838
Drug: atazanavir 300mg boosted with ritonavir 50 mg
RxNorm normalized name: atazanavir 300 MG
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)
Trial: NCT01088620
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression.
Trial: NCT01088620
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
Trial: NCT01088620
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
Trial: NCT02119663
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg tablets to be administered by mouth twice daily (BID)
Trial: NCT01688544
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10 mg for 7 days
Trial: NCT00928200
Drug: Erwinase
RxNorm normalized name: Erwinase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion.
Trial: NCT00928200
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
Trial: NCT00928200
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/m2/day divided BID. Give by mouth days 1-14.
Trial: NCT00928200
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
Trial: NCT00864344
Drug: Sertraline HCl 100 mg tablets, single dose
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental SSubjects received Purepac formulated products under fasting conditions
Trial: NCT00479349
Drug: SAM-531
RxNorm normalized name: SAM
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
Trial: NCT02613091
Drug: Clemastine fumarate
RxNorm normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg 2x day clemastine fumarate orally.
Trial: NCT04647695
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
Trial: NCT02863328
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration once-daily.